FORM 4

obligations may continue. See

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Or Yat Sun (Last) (First) (Middle) C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET					EN EN 3. E 03/	ENANTA PHARMACEUTICALS INC [ENTA] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2019 4. If Amendment, Date of Original Filed (Month/Day/Year)								(Check X	Adl applicable) Director 10% Owner Officer (give title Other (specify below) Sr. VP & CSO Aridual or Joint/Group Filing (Check Applicable			
(Street) WATERT (City)	TOWN M)2472 	2	-									X	•			
		Tabl	e I -	Non-Deriv	vative	Seci	uritie	s Ad	cqui	red, D	isposed o	of, or l	Benefic	ially (Owne	ed		
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/Y			Year)	2A. Deemed Execution Date, if any (Month/Day/Year		е,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			Sec Bei Ow		nount of rities ficially ed Following rted	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v .	Amount	(A) or (D)	Price		Trans	saction(s) . 3 and 4)		(11301 4)
Common Stock 03/01				03/01/20	19	.9			S ⁽¹⁾		5,910	D	\$103.32	3.3211(2)		04,763	D	
Common Stock 03/01/				03/01/20	19	.9			S ⁽¹⁾		4,090	D	\$103.8368(3)		3	00,673	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Security Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year)			4. Transa Code (8)	(Instr.	Str. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of		Deriv Secu (Insti		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2016
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$102.66 to \$103.62, inclusive.
- 3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$103.66 to \$104.20, inclusive.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3 above.

/s/ Nathaniel S. Gardiner as attorney-in-fact

03/01/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.